Shares of MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $12.00.
Several research analysts have recently commented on the stock. HC Wainwright decreased their price target on shares of MacroGenics from $16.00 to $4.00 and set a “neutral” rating for the company in a report on Monday, May 13th. Stifel Nicolaus lowered MacroGenics from a “buy” rating to a “hold” rating and lowered their target price for the company from $29.00 to $7.00 in a report on Friday, May 10th. BTIG Research cut their price target on MacroGenics from $24.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, May 24th. TD Cowen downgraded MacroGenics from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Finally, B. Riley started coverage on MacroGenics in a research note on Friday, April 26th. They issued a “buy” rating and a $25.00 target price on the stock.
Get Our Latest Analysis on MGNX
Institutional Investors Weigh In On MacroGenics
MacroGenics Stock Up 8.5 %
Shares of NASDAQ MGNX opened at $5.34 on Thursday. The stock’s 50 day moving average price is $4.50 and its two-hundred day moving average price is $11.48. MacroGenics has a 52-week low of $3.14 and a 52-week high of $21.88. The stock has a market capitalization of $334.46 million, a P/E ratio of -13.69 and a beta of 2.08.
MacroGenics (NASDAQ:MGNX – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.17). The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $13.63 million. MacroGenics had a negative net margin of 53.60% and a negative return on equity of 98.01%. On average, analysts anticipate that MacroGenics will post -3.04 EPS for the current year.
About MacroGenics
MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
Read More
- Five stocks we like better than MacroGenics
- Dividend Payout Ratio Calculator
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- Investing in Travel Stocks Benefits
- Has This Leading Tech Stock Halted the AI Surge?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.